Ascendis Pharma A/S (ASND) Q3 2022 Earnings Results

Ascendis Pharma Misses on EPS, Stock Down 2.37%

Ascendis Pharma reported a wider-than-expected loss per share, which contributed to a decline in stock price by 2.37%. The lack of revenue figures and management guidance adds uncertainty to the company's outlook. Investors may be cautious as they await more information from future reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-2.99	N/A	-20.59%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results. Therefore, there is no management commentary available.

Ascendis Pharma Misses on EPS, Stock Down 2.37%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma Misses on EPS, Stock Down 2.37%

Key numbers

Management commentary